<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Ital J Pediatr</journal-id>
<journal-id journal-id-type="iso-abbrev">Ital J Pediatr</journal-id>
<journal-title-group>
<journal-title>Italian Journal of Pediatrics</journal-title>
</journal-title-group>
<issn pub-type="epub">1824-7288</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30442188</article-id>
<article-id pub-id-type="pmc">6238256</article-id>
<article-id pub-id-type="publisher-id">561</article-id>
<article-id pub-id-type="doi">10.1186/s13052-018-0561-2</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Barone</surname>
<given-names>Rita</given-names>
</name>
<address>
<phone>095 378 2898</phone>
<email>rbarone@unict.it</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pellico</surname>
<given-names>Alessandra</given-names>
</name>
<address>
<email>alessandrapellico@tiscali.it</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pittalà</surname>
<given-names>Annarita</given-names>
</name>
<address>
<email>annaritapit@hotmail.it</email>
</address>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gasperini</surname>
<given-names>Serena</given-names>
</name>
<address>
<email>s.gasperini@hsgerardo.org</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1757 1969</institution-id><institution-id institution-id-type="GRID">grid.8158.4</institution-id><institution>Neuropsichiatria Infantile, Dipartimento di Medicina Clinica e Sperimentale, </institution><institution>Università di Catania, </institution></institution-wrap>Catania, Italy </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1757 1969</institution-id><institution-id institution-id-type="GRID">grid.8158.4</institution-id><institution>Centro di Riferimento Regionale per le malattie metaboliche congenite, Policlinico, </institution><institution>Università di Catania, </institution></institution-wrap>Catania, Italy </aff>
<aff id="Aff3"><label>3</label>UOS Malattie Metaboliche Rare, Clinica Pediatrica, Fondazione MBBM, ATS Monza, Monza, Italy </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1757 1969</institution-id><institution-id institution-id-type="GRID">grid.8158.4</institution-id><institution>Neuropsichiatria Infantile, Policlinico, Università di Catania, </institution></institution-wrap>Via S. Sofia 78, 95123 Catania, Italy </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>16</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>16</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>44</volume>
<issue>Suppl 2</issue>
<issue-sponsor>The publication costs for this supplement were made possible with unconditional financial support from BioMarin, Sanofi Genzyme, and Shire. The sponsors had no input into the content of articles, which were independently prepared by the authors and have undergone the journal’s standard peer-review process. RP has received reimbursements, fees and funding, from Sanofi Genzyme, Shire International, BioMarin, Ultragenyx, SOBI and Chiesi. FS is a Senior Editor of Italian Journal of Pediatrics, and declares no competing interests. MS has received honoraria for scientific expertise and seminars and research grants from Actelio, Biomarin, Chiesi, Sanofi Genzyme, SHIRE , Sangamo and Ultragenix. GA declares no competing interests. AB declares no competing interests. GP declares no competing interests.</issue-sponsor>
<elocation-id>121</elocation-id>
<permissions>
<copyright-statement>© The Author(s). 2018</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Mucopolysaccharidoses (MPS) are a group of lysosomal multisystemic, chronic, and progressive diseases characterized by the storage of glycosaminoglycans (GAGs) that may affect the central nervous system. Neuronopathic MPS such as MPS IH, MPS II, MPS IIIA–D, and MPS VII are characterized by neurocognitive regression. In severe MPS I (MPS IH, or Hurler syndrome) initial developmental trajectory is usually unremarkable but cognitive development shows a plateau by 2 to 4 years of age and then progressively regresses with aging. Patients with neuronopathic MPS II have a plateau of cognitive and adaptive development on average by 4 to 4.5 years of age, although there is significant variability, followed by progressive neurocognitive decline. In patients with classic MPS III, developmental trajectory reaches a plateau around 3 years of age, followed by regression. Sleep disturbances and behavioral problems occur early in MPS II and III with features of externalizing disorders. Acquired autism-like behavior is often observed in children with MPS III after 4–6 years of age. Impaired social and communication abilities do occur, but MPS III children do not have restricted and repetitive interests such as in autism spectrum disorder. MPS type VII is an ultra-rare neuronopathic MPS with a wide clinical spectrum from very severe with early mortality to milder phenotypes with longer survival into adolescence and adulthood. Most patients with MPS VII have intellectual disability and severely delayed speech development, usually associated with hearing impairment. Cognitive regression in neuronopathic MPS runs parallel to a significant decrease in brain tissue volume. Assessment of the developmental profile is challenging because of low cognitive abilities, physical impairment, and behavioral disturbances. Early diagnosis is crucial as different promising treatment approaches have been extensively studied in animal MPS models and are currently being applied in clinical trials.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Mucopolysaccharidoses</kwd>
<kwd>Cognition</kwd>
<kwd>Behavior</kwd>
<kwd>Assessment</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par24">Mucopolysaccharidoses (MPS) are a group of chronic and progressive lysosomal storage disorders caused by the defective degradation of glycosaminoglycans (GAGs). Progressive GAG accumulation in organs and tissues leads to the development of multisystem clinical manifestations. Somatic features are variable and may include coarse face, hepatosplenomegaly, skeletal and joint abnormalities, and cardiorespiratory disease [<xref ref-type="bibr" rid="CR1">1</xref>]. The central nervous system (CNS) is primarily affected in neuronopathic MPS I Hurler (MPS IH), II, III(A–D), and VII. Neuronopathic MPS are characterized by developmental delay and neurocognitive regression, behavioral changes and sleep disturbances, and epilepsy [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Brain changes associated with MPS disorders include atrophic changes and abnormalities in the white matter and perivascular spaces, communicating hydrocephalus, increased intracranial pressure, and compressive myelopathy [<xref ref-type="bibr" rid="CR3">3</xref>]. In MPS types IV and VI, cognitive development is not affected although patients may have secondary neurological complications such as hydrocephalus and cervical spine cord compression [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. The pathophysiology of neuronal damage in neuronopathic MPS is related to the storage of undegraded GAG, in particular heparan sulfate (HS), and secondary toxic products such as GM2 and GM3 gangliosides, inflammatory cytokines, and reactive oxygen species [<xref ref-type="bibr" rid="CR4">4</xref>]. Although all neuronopathic MPS are characterized by neuronal storage of products from incomplete HS degradation, the behavioral phenotype is variable. Behavioral problems represent hallmark features of severe MPS II and MPS III [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR8">8</xref>]. Unlike MPS II and III, children with MPS IH are generally placid, gentle, and calm, although intellectual disability does occur and progress [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. It has been hypothesized that, in patients with MPS II and III, distinct chemical moieties occurring at the ends of incompletely degraded HS molecules may interfere with neuronal function due to chemical reactions and this might be related to the occurrence of behavioral problems [<xref ref-type="bibr" rid="CR9">9</xref>]. Patients with neuronopathic MPS I, II, III, and VII present with developmental delay, plateauing, and cognitive regression [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Hyperactive behavior is highly prevalent in neuronopathic MPS II and is considered among the early clinical markers of CNS involvement in patients with MPS II [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. MPS III patients behave as hyperactive and impulsive children and appear prone to dangerous behavior, often leading to body injuries [<xref ref-type="bibr" rid="CR8">8</xref>]. Lack of fear and poor attention similar to a Klüver Bucy-like syndrome and autistic-like symptomatology have been reported in patients with MPS IIIA [<xref ref-type="bibr" rid="CR10">10</xref>] and IIIB [<xref ref-type="bibr" rid="CR11">11</xref>]. Severe sleeping disturbances, temper tantrums, easy irritability, and mood changes also occur in patients with MPS II and III [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Epilepsy has a higher prevalence in neuronopathic MPS II and MPS III, with an incidence that increases with advancing neurocognitive regression. Seizures typically present with the features of generalized tonic-clonic seizures. Absence epilepsy, tonic, focal and myoclonic seizures and nonconvulsive status epilepticus have been also reported [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p>
<p id="Par25">The therapy for neuronopathic MPS is aimed at correcting enzyme deficiency and/or substrate accumulation in the brain. Experimental approaches using MPS animal models have produced promising results and led to clinical trials in patients with neuronopathic MPS [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Knowledge on the presentation and clinical course of neuronopathic MPS may be advantageous for early diagnosis and possible early intervention. In this regard, we here report on the main current topics on neurobehavioral phenotypes and summarize therapeutic advances in the cure of neuronopathic MPS.</p>
</sec>
<sec id="Sec2">
<title>Developmental and behavioral patterns of MPS</title>
<sec id="Sec3">
<title>Mucopolysaccharidosis type I</title>
<p id="Par26">Mucopolysaccharidosis type I (MPS I) is caused by a deficiency of alpha-<sc>l</sc>-iduronidase (IDUA) and storage of HS and dermatan sulfate (DS). Prevalence is estimated to be 1/100,000. Based on age at onset, and the presence or absence of cognitive decline and the severity of systemic disease, MPS I is classified as either Hurler syndrome (severe phenotype), Hurler-Scheie (intermediate phenotype), or Scheie syndrome (mild phenotype) [<xref ref-type="bibr" rid="CR1">1</xref>]. Children with Hurler syndrome (MPS IH) develop normally in the first months of life. Slowing of development milestones occurs by 12 months of age, and global developmental delay (mental development quotient more than two standard deviations (SDs) below the mean) may be observed by 2 years of age. Patients usually have a stasis of cognitive development by 2 to 4 years of age followed by rapid regression with aging [<xref ref-type="bibr" rid="CR5">5</xref>]. Although motor problems, hydrocephalus, visual, and hearing defects contribute to poor cognition, developmental slowness and regression occur independently and reflect primary CNS disease [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. In patients with MPS IH, hematopoietic stem cell transplantation (HSCT) halts the inexorable cognitive decline [<xref ref-type="bibr" rid="CR17">17</xref>–<xref ref-type="bibr" rid="CR19">19</xref>]. A recent, multicenter survey in the US showed that all of 22 untransplanted children with MPS IH were in the impaired cognitive range (greater than two SDs below the mean) at 27 months of age [<xref ref-type="bibr" rid="CR18">18</xref>]. HSCT is currently considered the treatment of choice for patients younger than 2.5 years [<xref ref-type="bibr" rid="CR20">20</xref>]. Prospectively collected longitudinal data showed that a very young age at transplantation (&lt; 9 months of age) was related to optimal cognitive, language, and adaptive performances in patients with MPS IH [<xref ref-type="bibr" rid="CR21">21</xref>]. A retrospective study of 217 transplanted MPS IH patients with a median follow-up age of 9.2 years demonstrated a significant amelioration of the MPS IH clinical course after HSCT. A younger age and preservation of cognitive function at transplantation were major predictors for better cognitive outcome post-transplant [<xref ref-type="bibr" rid="CR22">22</xref>]. In addition, a significant residual disease burden was observed in the transplanted patients with MPS IH, such as growth retardation and specific systemic problems. A normal leukocyte alpha-iduronidase enzyme level obtained post-HSCT was a predictor for better clinical outcome in most organ systems [<xref ref-type="bibr" rid="CR22">22</xref>]. Neuropsychological assessment in transplanted patients with MPS IH showed that despite a normal full-scale IQ, patients with MPS IH after successful HSCT may have decreased attention span and information processing. Decrease in white matter integrity and reduction of corpus callosum volume are associated with defects in attention tasks in these patients [<xref ref-type="bibr" rid="CR23">23</xref>].</p>
<p id="Par27">There is no cognitive decline associated with attenuated MPS I Scheie (MPS IS), with the exception of patients bearing the L238Q missense mutation paired with a nonsense mutation. These patients present with late-onset brain disease as cognitive decline starts at a later age than is seen with Hurler syndrome, and psychiatric problems emerge in adolescence [<xref ref-type="bibr" rid="CR24">24</xref>]. The extent of systemic disease burden may act as a predictor of cognitive performance in patients with attenuated MPS I. Recently, Ahmed et al. [<xref ref-type="bibr" rid="CR25">25</xref>] demonstrated that, in attenuated MPS I Hurler/Scheie (HS) and MPS IS, somatic disease burden measured by the Physical Symptom Score (PSS) was negatively associated with cognitive level (full-Scale IQ) (<italic>p</italic> &lt; 0.001), indicative that both measures reflect disease severity [<xref ref-type="bibr" rid="CR25">25</xref>]. In addition, physical disease and sensorial defects cause functional impairment and reduce academic performances in attenuated MPS I individuals. Enzyme replacement therapy (ERT) is the first-choice therapy for patients with attenuated MPS I. A retrospective case series including 20 patients with Hurler-Scheie syndrome within nine sibships showed that, in younger siblings, somatic signs did not develop or progress when they were absent or mild at ERT initiation. Improvements in physical disease following ERT as well as interventions including hearing aids, physical therapy, and speech therapy may result in amelioration of adaptive functioning and improved quality of life for patients with attenuated MPS I [<xref ref-type="bibr" rid="CR26">26</xref>].</p>
<p id="Par28">Newborn screening for MPS I will benefit the identification of severely affected patients and help early treatment [<xref ref-type="bibr" rid="CR27">27</xref>]. Before newborn screening programs are implemented, awareness of MPS I among pediatricians and primary care providers is crucial for patient identification and prompt initiation of treatment (see also the review by Donati et al. [<xref ref-type="bibr" rid="CR28">28</xref>] in this Supplement).</p>
<p id="Par29">In summary, patients with MPS I Hurler have developmental delay by 12 months and stagnation of cognitive development by 2 to 4 years of age followed by rapid regression with aging. Hematopoietic stem cell transplantation is the standard treatment to prevent and to halt neurocognitive regression with an earlier age of treatment associated with improved outcomes.</p>
</sec>
<sec id="Sec4">
<title>Mucopolysaccharidosis type II (Hunter syndrome)</title>
<p id="Par30">Hunter syndrome (MPS II) is an X-linked, multisystem disorder characterized by iduronate sulfatase (IDS) deficiency which results in the accumulation of DS and HS. MPS II prevalence is around 1 in 100,000 male births. Presentation in females with skewed inactivation of the X chromosome is uncommon [<xref ref-type="bibr" rid="CR1">1</xref>]. There is high clinical variability among patients with the same mutation, suggesting epigenetic influences in the clinical expression. Systemic manifestations of MPS II include coarse face, skeletal anomalies and joint restriction, cardiac valve disease, and hepatosplenomegaly. Based on the presence or absence of progressive neurological involvement and behavioral problems, patients with MPS II are classified as neuronopathic or attenuated, respectively [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Although there is a significant variability and the likelihood of a long-lasting developmental plateau in some patients, neuronopathic MPS II shows a plateau of cognitive and adaptive development on average at 4 to 4.5 years of age, followed by progressive neurocognitive regression [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Neurological findings of severe MPS II include progressive impairment of gross and fine motor abilities, epilepsy, sensorineural deafness with severe language disturbance and loss of verbal language, retinal degeneration, and sleep problems [<xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR7">7</xref>]. Seizures are frequently observed most often as staring episodes, myoclonus, and tonic-clonic seizures [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Sleeping problems can be secondary to CNS involvement, obstructive apnea, or both [<xref ref-type="bibr" rid="CR29">29</xref>]. Sleep disturbances present as difficulty initiating or maintaining sleep. A decrease in rapid eye movement sleep duration, atypical sleep stage distribution, and frequent leg movements when falling asleep may be observed [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. A retrospective analysis of neurodevelopmental profile in 49 children with MPS II including 37 participants with neurological deterioration detected early signs and symptoms associated with neuronopathic MPS II [<xref ref-type="bibr" rid="CR7">7</xref>]. Seven clinical markers were identified as early predictors of cognitive dysfunction: increased activity, behavior difficulties, sleep disturbance, seizure-like behavior, perseverative chewing, and an inability to achieve sphincter control. Increased activity manifested as “high-energy behavior” and inability to focus on tasks. An index of severity score was developed, with a score ≥ 3 indicating a high likelihood of developing brain disease [<xref ref-type="bibr" rid="CR7">7</xref>]. Such findings highlight the importance of monitoring development in children with MPS II to identify early those children who may benefit from brain-targeted therapy. Somatic disease manifestations of MPS II are controlled by intravenous ERT, while this is ineffective in preventing or treating CNS involvement [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Among brain-targeted therapy, direct delivery of ERT in the cerebrospinal fluid (CSF) has been investigated in animal models of MPS II, and a phase 1/2 study reported the safety of intrathecal (IT) administration of idursulfase formulated for IT use in patients with neuronopathic MPS II [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
<p id="Par31">Brain changes associated with MPS II include perivascular space enlargement, white matter abnormalities, subarachnoid space enlargement, third ventricle dilatation, hydrocephalus, and brain atrophy [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. An elevated myoinositol/creatine ratio in the gray and white matter are more frequently observed in MPS II patients with neurocognitive impairment [<xref ref-type="bibr" rid="CR32">32</xref>]. Likewise, volumetric magnetic resonance studies show significant atrophic changes in brain tissue in MPS II patients with neurological morbidity [<xref ref-type="bibr" rid="CR33">33</xref>]. Patients with attenuated MPS II have normal cognitive development or mild impairment [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Despite a normal IQ, attenuated MPS II patients treated with ERT may have a decreased attention span and impaired visual processing related to decreased volumes of white matter and corpus callosum [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
<p id="Par32">In summary, although there is a significant variability in patients with neuronopathic MPS II, cognitive development reaches a plateau on average at 4 to 4.5 years of age, followed by progressive regression. Behavioral and sleep problems represent early clinical markers of CNS involvement in patients with neuronopathic MPS II. Emerging promising treatments for neuronopathic MPS II such as IT-ERT are being evaluated.</p>
</sec>
<sec id="Sec5">
<title>Mucopolysaccharidosis type III (Sanfilippo syndrome)</title>
<p id="Par33">Sanfilippo syndrome (MPS III) includes four autosomal recessive disorders (MPS III A–D) caused by deficiency of different lysosomal enzymes required for the degradation of HS. MPS III are the most frequent among MPS disorders with an overall prevalence of 1.5–1.9 per 100,000 live births [<xref ref-type="bibr" rid="CR1">1</xref>]. MPS III are neurodegenerative disorders characterized by regression of intellectual and motor abilities, behavioral problems, and dementia, with death usually in the second decade of life [<xref ref-type="bibr" rid="CR2">2</xref>]. Developmental delay and, in particular, speech delay are common presenting features of MPS III. Patients with the classic severe phenotypes have developmental plateau at around 3 years of age followed by rapid regression of language, cognition, and adaptive functions, with longer preservation of motor abilities [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR35">35</xref>–<xref ref-type="bibr" rid="CR39">39</xref>]. In addition to the severe phenotype, there are patients with attenuated MPS III showing a slowly progressing course with long periods of stable intellectual disability and gradual cognitive decline even in adulthood [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. A prospective study of MPS IIIA classified two groups of patients as rapid and slow progressive, respectively, differing in their natural histories of cognitive and brain changes [<xref ref-type="bibr" rid="CR39">39</xref>]. Children with rapid progression usually presented with a mean loss of –14.6 DQ points per year at an age below 6 years. On the other hand, patients with slow progression had a mean DQ reduction of –3.7 points per year. Cognitive decline ran parallel to brain atrophy and was related to a consistent decrease in cortical gray matter volume [<xref ref-type="bibr" rid="CR39">39</xref>]. Neuropsychiatric abnormalities in MPS III are classified according to a triphasic model [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. In the first 1 to 2 years, patients have a developmental delay, in particular for speech abilities (the beginning phase). Almost half of patients will never be toilet trained. At an average of 2 to 4 years of age (the middle phase), behavioral abnormalities become evident with increasingly frequent and severe temper tantrums. Patients have anxiety symptoms with panic attacks when they are in an unfamiliar environment and display phobias. This is followed by hyperactivity and a decreased attention span and impulsive behavior. The late phase of disease starts at around 10 years and it is characterized by a decrease in challenging behavior and increases in motor difficulties, spasticity, loss of balance, and feeding disturbances. Children with MPS III have significantly more behavioral problems relating to hyperactivity, orality, body movements, and inattention compared with matched controls with intellectual disability [<xref ref-type="bibr" rid="CR42">42</xref>]. Epilepsy including generalized tonic-clonic seizures, tonic, focal and myoclonic seizures, and nonconvulsive status-epilepticus may occur in the later stages of the disease [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Recently the Sanfilippo Behavior Rating Scale (SBRS) has been developed to quantify and to monitor behavioral changes in Sanfilippo syndrome. The scale includes four abnormality clusters—movement, lack of fear, social/emotional, and executive dysfunction—and may be helpful for measuring behavioral changes that accompany disease progression [<xref ref-type="bibr" rid="CR43">43</xref>].</p>
<p id="Par34">Sleep alterations are an almost constant feature of MPS III. Sleep disturbances have been characterized by parental sleep questionnaires [<xref ref-type="bibr" rid="CR44">44</xref>] and objectively recorded by polysomnography [<xref ref-type="bibr" rid="CR45">45</xref>] and actigraphy [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Patients with MPS III have significant longer sleep onset latencies and problems with failing to fall asleep and greater daytime sleep compared with controls. Sleep problems result in very frequent nocturnal waking and wandering, with personal and familial distress [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. MPS III mice show modifications in the circadian rhythm that correlate with lysosomal storage and changes in circadian neuropeptides in the suprachiasmatic nucleus that is the main biological pacemaker in mammals [<xref ref-type="bibr" rid="CR48">48</xref>]. Patients with MPS III show significantly increased fragmentation of circadian rhythm and abnormal endogenous melatonin concentrations [<xref ref-type="bibr" rid="CR47">47</xref>]. Exogenous melatonin administration is effective in most MPS III patients [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. Around the age of 4 years, MPS III patients may show acquired symptoms of autism spectrum disorder (ASD) such as impaired social reciprocity and communication. Unlike children with idiopathic ASD, social and communicative symptoms are evident later than 3 years of age and, apart from hyperorality, MPS III children do not present with restricted interests or repetitive behavior [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. The diagnosis of MPS III may be overlooked because of the lack of early somatic signs associated with mucopolysaccharide storage disorders [<xref ref-type="bibr" rid="CR8">8</xref>]. Moreover, children with MPS III may be initially misdiagnosed with ASD and/or other neurodevelopmental disorders (i.e., developmental delay, language delay, attention deficit disorder with hyperactivity) because clinicians tend to focus on neurodevelopmental delay and behavioral problems that are prominent presenting features [<xref ref-type="bibr" rid="CR51">51</xref>]. Since typically developing children have a rapid development in the first years of life, developmental plateauing at this time and/or the occurrence of behavioral problems and sleep disturbances should prompt diagnostic analyses for underlying diseases such as Sanfilippo disease even in the absence of overt somatic MPS features. Different approaches to treat brain disease such as phase 1/2 clinical trials using IT-ERT or gene therapy have been performed in patients with MPS IIIA and IIIB [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
<p id="Par35">In summary, patients with MPS III and rapidly progressing phenotypes have a development plateau around 3 years of age followed by progressive decline. Patients with attenuated phenotypes may have a long period of stable intellectual disability before regression. MPS III may be initially misdiagnosed because of the lack of early somatic signs associated with MPS. Emerging promising treatments for brain disease in MPS III have been developed and are being used in phase 1/2 clinical trials.</p>
</sec>
<sec id="Sec6">
<title>Mucopolysaccharidosis type VII (Sly syndrome)</title>
<p id="Par36">Sly syndrome or MPS VII is a very rare neuronopathic MPS characterized by a deficiency of the lysosomal enzyme β-glucuronidase. MPS VII features include coarse face, short stature, skeletal disease, joint stiffness, hepatosplenomegaly, and cardiorespiratory disease. CNS involvement is prominent in patients with MPS VII. Neurological features include global developmental delay, speech delay, intellectual disability of variable degree, sensorineural deafness, hydrocephalus, and spinal cord compression [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. The disease shows a wide range of clinical variability. Based on their phenotype, patients with MPS VII have been recently classified into three different groups. Nonimmune neonatal hydrops fetalis patients (the first group) have severe multisystemic disease and survive a few months. Patients with infantile or adolescent forms with or without history of hydrops fetalis (the second and third groups, respectively) vary from mild to moderate or severe phenotypes independent of the occurrence of neonatal hydrops fetalis [<xref ref-type="bibr" rid="CR53">53</xref>]. Somatic features of patients with MPS VII resemble those of MPS I and MPS II; however, the frequent occurrence of nonimmune hydrops fetalis (almost 40% of patients) is a distinguishing clinical feature [<xref ref-type="bibr" rid="CR54">54</xref>]. Global developmental delay and intellectual disability (mild, moderate to severe), limited vocabulary, and speech disturbance are common. Hearing impairment is frequent and likely contributes to speech disturbance [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. Patients usually require special education. A survey on the clinical course of MPS VII reported that 17% of 46 patients with infantile or adolescent forms were able to perform daily activities by themselves, while most patients required assistance. Almost 50% of patients could walk without support, although most patients lost this ability. Patients with mild or moderate early manifestations tended to deteriorate more slowly than patients with more severe manifestations [<xref ref-type="bibr" rid="CR53">53</xref>]. Treatment approaches for MPS VII including bone marrow transplantation (BMT), ERT, and gene therapy are very promising [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. Information on patients with MPS VII that underwent BMT at variable ages and disease stages suggest that engrafted BMT may slow or prevent neurological deterioration [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. Investigational therapy with recombinant human β-glucuronidase (rhGUS) over 24 weeks in a 12-year-old boy with advanced stage MPS VII was associated with a reduction in urinary GAG, normalization of liver and spleen sizes, improvement of pulmonary function, and increased activity level and quality of life [<xref ref-type="bibr" rid="CR57">57</xref>]. Clinical trials of ERT on patients with MPS VII are underway.</p>
<p id="Par37">In summary, patients with MPS VII have a prominent CNS involvement and somatic features resembling those of MPS I and MPS II. Novel promising treatments for MPS VII such as intravenous ERT are being employed in clinical trials.</p>
</sec>
</sec>
<sec id="Sec7">
<title>Cognitive assessment tools in children with MPS</title>
<p id="Par38">Cognitive measurements in MPS are particularly important for natural history studies and are increasingly required to compare efficacy across clinical trials. A definition of cognitive outcome measures is challenging due to the rarity and specific features of MPS patients. Assessment protocols need to be uniform to make data comparable across ages. The formal assessment of cognitive functions in patients with MPS II and III poses several major challenges because of physical and behavioral limitations in this population. Detailed information on neurocognitive assessment in patients with MPS have been reported [<xref ref-type="bibr" rid="CR58">58</xref>–<xref ref-type="bibr" rid="CR62">62</xref>]. Cognitive endpoints for therapy development were discussed in a consensus paper [<xref ref-type="bibr" rid="CR63">63</xref>]. General issues include the use of age-equivalent measures, especially at younger ages, to evaluate changes over time as well as the need for precise, simple measurements, to control the testing environment, and to use the appropriate test for the estimated developmental age [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR58">58</xref>–<xref ref-type="bibr" rid="CR63">63</xref>]. The main cognitive assessment tests employed in patients with neuronopathic MPS according to age are reported in (Table <xref ref-type="table" rid="Tab1">1</xref>). The Griffiths’ Mental Development Scales-II, the Bayley Scales of Infant Development (BSID)-III or the Kaufman Assessment Battery for Children (KABC)-II have been used in children with MPS under 3 years of age or those with an estimated developmental age ≤ 3 years [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. The BSID-III age-equivalent and developmental quotients have been suggested in patients with MPS I [<xref ref-type="bibr" rid="CR18">18</xref>] and MPS III [<xref ref-type="bibr" rid="CR58">58</xref>]. The disadvantage of BSID-III is its limited age range that requires a transition to different tools over time. The Mullen Scales of Early Learning (MSEL), mostly used in the US, are applicable from 0 to 68 months of age and have been proven to measure disease-related changes in MPS II [<xref ref-type="bibr" rid="CR6">6</xref>], III [<xref ref-type="bibr" rid="CR38">38</xref>], and in MPS I patients post-HSCT [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. The Wechsler scales (Wechsler Preschool and Primary Scale of Intelligence (WPPSI), Wechsler Intelligence Scale for Children (WISC), and Wechsler Adult Intelligence Scale (WAIS)) are structurally similar and, by covering a wide range of ages, have been used in MPS-I post-HSCT and in other MPS over the age of 3 years whenever possible [<xref ref-type="bibr" rid="CR61">61</xref>–<xref ref-type="bibr" rid="CR63">63</xref>]. MPS patients have limitations due to motor disability, visual and hearing defects, and behavioral problems. The Wechsler Abbreviated Scale of Intelligence (WASI)-II is short and does not penalize patients with motor difficulties or slow processing speed; it has already been used in patients with MPS-I [<xref ref-type="bibr" rid="CR23">23</xref>] and II [<xref ref-type="bibr" rid="CR34">34</xref>]. The Wechsler scales demanding fine motor skills, sustained attention, and processing speed are not feasible in patients with MPS II and III with low cognitive levels and behavioral concerns. The Vineland Adaptive Behavior Scales (VABS)-II is parent observation of adaptive behavior administered by interview that includes communication, daily living skills, socialization, and motor skills. The VABS are recommended for measuring adaptive behavior in patients with MPS at all ages [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>] and allow parent-reported age-equivalent scores to be obtained and compared with those of the cognitive measures [<xref ref-type="bibr" rid="CR58">58</xref>]. In conclusion, cognitive assessment tools in patients with neuronopathic MPS should take into account the proper clinical features of this population. The assessment of these children requires a quiet environment facilitating concentration; to obtain this, the child is rested and calm during the assessment, and this should be performed preferably as the first test after admission to hospital before other stressful examinations [<xref ref-type="bibr" rid="CR38">38</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>Neurocognitive tests employed in patients with neuronopathic MPS according to age</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th colspan="3">Tests employed</th><th>References</th></tr></thead><tbody><tr><td>Age ≤ 36 months</td><td>BSID-III</td><td>MSEL</td><td>GMDS-III</td><td></td></tr><tr><td> Range<sup>a</sup></td><td>0–42 months</td><td>0–68 months</td><td>0–72 months</td><td></td></tr><tr><td> Natural history, MPS characteristic studies</td><td>MPS I, II, III</td><td>MPS I, II, III</td><td>MPS III</td><td>[<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]</td></tr><tr><td> Treatment outcome</td><td>MPS I (HSCT), MPS II (ERT); MPS IIIA (IT-ERT)</td><td>MPS I (HSCT)</td><td>MPS I (HSCT, ERT), MPS II (HSCT, ERT), MPS III (HSCT)</td><td>[<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]</td></tr><tr><td>Age &gt; 36 months, ≤ 6 years</td><td>KABC-II</td><td>Leiter-III</td><td>WPPSI-IV</td><td></td></tr><tr><td> Range<sup>a</sup></td><td>3–18 years</td><td>3–75 years</td><td>2.6–7.7 years</td><td></td></tr><tr><td> Natural history, MPS characteristic studies</td><td>MPS III</td><td>–</td><td>MPS I, II</td><td>[<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]</td></tr><tr><td> Treatment outcome</td><td>–</td><td>MPS I ((HSCT), MPS III (HSCT)</td><td>MPS I (HSCT)</td><td>[<xref ref-type="bibr" rid="CR60">60</xref>–<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td>Age &gt; 6 years and adulthood</td><td>WISC-IV</td><td>WAIS-IV</td><td>WASI</td><td></td></tr><tr><td> Range<sup>a</sup></td><td>6.0–16.11 years</td><td>16–90 years</td><td>6–89 years</td><td></td></tr><tr><td> Natural history, MPS characteristic studies</td><td>MPS II, III</td><td>MPS I, II, III</td><td>MPS I, II</td><td>[<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR60">60</xref>–<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td> Treatment outcome</td><td>MPS I (HSCT)</td><td>MPS I (HSCT)</td><td>MPS I (HSCT)</td><td>[<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR60">60</xref>–<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic>BSID</italic> Bayley Scales of Infant Development, <italic>ERT</italic> enzyme replacement therapy, <italic>GMDS</italic> Griffiths Mental Development Scales, <italic>HSCT</italic> hematopoietic stem cell transplantation, <italic>IT</italic> intrathecal, <italic>KABC</italic> Kaufman Assessment Battery for Children, <italic>MPS</italic> mucopolysaccharidosis, <italic>MSEL</italic> Mullen Scales of Early Learning, <italic>WAIS</italic> Wechsler Adult Intelligence Scale, <italic>WASI</italic> Wechsler Abbreviated Scale of Intelligence, <italic>WISC</italic> Wechsler Intelligence Scale for Children, <italic>WPPSI</italic> Wechsler Preschool and Primary Scale of Intelligence</p><p><sup>a</sup> Range of age referred according to manual</p></table-wrap-foot></table-wrap></p>
<p id="Par39">In summary, cognitive function should be measured by age-equivalent scores in neuronopathic MPS patients. Assessment tools should be selected taking into account the physical, sensorial, and behavioral limitations present in MPS patients.</p>
</sec>
<sec id="Sec8">
<title>Principles of treatment of neuronopathic MPS</title>
<p id="Par40">Currently, different brain-targeted approaches are in preclinical and clinical development with the aim of preventing or halting primary CNS involvement of MPS. HSCT aims to deliver donor stem cells that produce the deficient enzyme in lysosomal storage disorders [<xref ref-type="bibr" rid="CR19">19</xref>]. HSCT is a consolidated and effective therapy to treat brain disease manifestations in MPS IH [<xref ref-type="bibr" rid="CR17">17</xref>]. The experience of HSCT in the treatment of other neuronopathic MPS is limited, although it appears to have a modest impact on neurological disease in patients with MPS II and III treated in the early stages of the disease [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. At this time, intravenous ERT represents an effective cure for systemic manifestations of MPS I, II, IVA, and VI, leading to improvement in the disease features and patient quality of life (see also the review by Concolino et al in this Supplement [<xref ref-type="bibr" rid="CR66">66</xref>]). The efficacy of investigational therapy with intravenous recombinant human β-glucuronidase (rhGUS) over 24 weeks was shown in a patient with advanced stage MPS VII [<xref ref-type="bibr" rid="CR57">57</xref>]. The selective permeability of the blood–brain barrier (BBB) hampers the effects of systemic intravenous ERT on the CNS due to the limitations of large enzyme molecules crossing the BBB and preventing neurodegeneration [<xref ref-type="bibr" rid="CR16">16</xref>]. New promising treatments for neuronopathic MPS disorders include direct delivery of ERT into the CNS through either intracerebroventricular injection or IT injection via an IT drug delivery device (IDDD) into the lumbar spine or subarachnoid space at the cisterna magna [<xref ref-type="bibr" rid="CR67">67</xref>]. Direct delivery of ERT in the CSF has been extensively tested in animal models of neuronopathic MPS I [<xref ref-type="bibr" rid="CR68">68</xref>], II [<xref ref-type="bibr" rid="CR69">69</xref>], and III [<xref ref-type="bibr" rid="CR70">70</xref>]. Phase 1/2 safety trials of IT-ERT in patients with MPS I [<xref ref-type="bibr" rid="CR71">71</xref>], MPS II [<xref ref-type="bibr" rid="CR72">72</xref>], MPS IIIA [<xref ref-type="bibr" rid="CR73">73</xref>], and IIIB [<xref ref-type="bibr" rid="CR74">74</xref>] have been published. Recent advances in genetic therapies including development of gene vectors and delivery routes are very promising for treating the neurologic manifestations of MPS [<xref ref-type="bibr" rid="CR75">75</xref>]. A phase 1/2 study evaluating the effects of intracerebral injection of adeno-associated viral vector rh.10-SGSH-IRES-SUMF1 and immunosuppressive treatment in four children with MPS IIIA showed a good safety profile and suggested moderate amelioration in behavior, attention, and sleep in the first year after surgery [<xref ref-type="bibr" rid="CR76">76</xref>]. Recently, a phase 1/2 clinical trial was conducted in four children with MPS IIIB aged 20, 26, 30, and 53 months. A recombinant adeno-associated viral vector serotype 2/5 (rAAV2/5) encoding human α-<italic>N</italic>-acetylglucosaminidase (NAGLU) plus immunosuppressive therapy was used. The study showed good safety and tolerability and induced sustained enzyme production in the brain. There was an improvement in neurocognitive progression compared with the natural history of MPS III, although a longer follow-up was envisaged to assess safety outcomes and persistency of improved cognitive development [<xref ref-type="bibr" rid="CR77">77</xref>]. Additional promising approaches for the treatment of CNS disease in MPS include enzyme-fusion protein technology (Trojan horse strategy), substrate reduction therapy, chaperone molecules, and the use of nanoparticle-delivered therapy [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>] (see also the reviews by Fecarotta et al. [<xref ref-type="bibr" rid="CR80">80</xref>] and Fraldi et al. [<xref ref-type="bibr" rid="CR81">81</xref>] in this Supplement). In addition to the treatment of primary CNS disease, children with MPS benefit from adjunctive therapies such as speech/language therapy, and occupational and physical therapy. Practical interventions, environmental changes, and behavioral interventions can be helpful in managing behavioral and sleep problems [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. A number of antiepileptic drugs (AED) have been used to treat epilepsy in patients with MPS. Monotherapy is generally effective, but less frequently two AED may be required for controlling seizures [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. The experience with behavior-modifying medications is most often empirical [<xref ref-type="bibr" rid="CR12">12</xref>]. In patients with MPS, the risk of side effects is high for antipsychotics along with the occurrence of paradoxical effects of anti-anxiety drugs, such as over-activity or over-sedation [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Melatonin use is considered effective in the management of sleep disturbances [<xref ref-type="bibr" rid="CR44">44</xref>], consistent with proven altered circadian rhythm in children with MPS III [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>].</p>
</sec>
<sec id="Sec9">
<title>Conclusions</title>
<p id="Par41">Neurocognitive evaluation in children with neuronopathic MPS may be challenging because of possible very low cognitive functions and behavioral disturbances, and sensorial and physical impairments. A careful preliminary clinical evaluation should be performed to recognize or exclude hearing loss (acute or chronic, conductive or sensorineural), difficulties in fine hand movements due to bone deformities and joint stiffness, and other orthopedic disturbances that impair activities requiring strength or balancing. Accurate assessment is required in these children to monitor early disease progression and outcome, particularly in view of the novel therapeutic approaches available. Knowledge of the neurobehavioral phenotypes of MPS may be critical for recognition, early diagnosis, and intervention programming and monitoring. It can be helpful for families in order to plan the future care of their child.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>AED</term>
<def>
<p id="Par2">Antiepileptic drugs</p>
</def>
</def-item>
<def-item>
<term>ASD</term>
<def>
<p id="Par3">Autism spectrum disorder</p>
</def>
</def-item>
<def-item>
<term>BBB</term>
<def>
<p id="Par4">Blood–brain barrier</p>
</def>
</def-item>
<def-item>
<term>BMT</term>
<def>
<p id="Par5">Bone marrow transplantation</p>
</def>
</def-item>
<def-item>
<term>BSID</term>
<def>
<p id="Par6">Bayley Scales of Infant Development</p>
</def>
</def-item>
<def-item>
<term>CNS</term>
<def>
<p id="Par7">Central nervous system</p>
</def>
</def-item>
<def-item>
<term>CSF</term>
<def>
<p id="Par8">Cerebrospinal fluid</p>
</def>
</def-item>
<def-item>
<term>DS</term>
<def>
<p id="Par9">Dermatan sulfate</p>
</def>
</def-item>
<def-item>
<term>ERT</term>
<def>
<p id="Par10">Enzyme replacement therapy</p>
</def>
</def-item>
<def-item>
<term>GAG</term>
<def>
<p id="Par11">Glycosaminoglycan</p>
</def>
</def-item>
<def-item>
<term>GMDS</term>
<def>
<p id="Par12">Griffiths Mental Development Scales</p>
</def>
</def-item>
<def-item>
<term>HS</term>
<def>
<p id="Par13">Heparan sulfate</p>
</def>
</def-item>
<def-item>
<term>HSCT</term>
<def>
<p id="Par14">Hematopoietic stem cell transplantation</p>
</def>
</def-item>
<def-item>
<term>IT</term>
<def>
<p id="Par15">Intrathecal</p>
</def>
</def-item>
<def-item>
<term>KABC</term>
<def>
<p id="Par16">Kaufman Assessment Battery for Children</p>
</def>
</def-item>
<def-item>
<term>MPS</term>
<def>
<p id="Par17">Mucopolysaccharidosi(e)s</p>
</def>
</def-item>
<def-item>
<term>MSEL</term>
<def>
<p id="Par18">Mullen Scales of Early Learning</p>
</def>
</def-item>
<def-item>
<term>VABS</term>
<def>
<p id="Par19">Vineland Adaptive Behavior Scales</p>
</def>
</def-item>
<def-item>
<term>WAIS</term>
<def>
<p id="Par20">Wechsler Adult Intelligence Scale</p>
</def>
</def-item>
<def-item>
<term>WASI</term>
<def>
<p id="Par21">Wechsler Abbreviated Scale of Intelligence</p>
</def>
</def-item>
<def-item>
<term>WISC</term>
<def>
<p id="Par22">Wechsler Intelligence Scale for Children</p>
</def>
</def-item>
<def-item>
<term>WPPSI</term>
<def>
<p id="Par23">Wechsler Preschool and Primary Scale of Intelligence</p>
</def>
</def-item>
</def-list>
</glossary>
<ack>
<title>Acknowledgements</title>
<p>The authors thank the MPS patients and their families.</p>
<sec id="FPar1">
<title>Funding</title>
<p id="Par42">The publication costs for this paper in the IJP supplement were made possible with unconditional financial support from BioMarin, Sanofi Genzyme, and Shire. The sponsors had no input into the content of articles, which were independently prepared by the authors and have undergone the journal’s standard peer-review process.</p>
</sec>
<sec id="FPar2">
<title>Availability of data and materials</title>
<p id="Par43">Not applicable.</p>
</sec>
<sec id="FPar3">
<title>About this supplement</title>
<p id="Par44">This article has been published as part of <italic>Italian Journal of Pediatrics,</italic> Volume 44 Supplement 2, 2018: Mucopolysaccharidoses: state of the art. The full contents of the supplement are available online at <ext-link ext-link-type="uri" xlink:href="https://ijponline.biomedcentral.com/articles/supplements/volume-44-supplement-2">https://ijponline.biomedcentral.com/articles/supplements/volume-44-supplement-2</ext-link> .</p>
</sec>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>RB wrote the first draft. All authors read and approved the final manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<sec id="FPar4">
<title>Ethics approval and consent to participate</title>
<p>Not applicable.</p>
</sec>
<sec id="FPar5">
<title>Consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec id="FPar6">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<sec id="FPar7">
<title>Publisher’s Note</title>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Neufeld</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Muenzer</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Scriver</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Beaudet</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sly</surname>
<given-names>WS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The mucopolysaccharidoses</article-title>
<source/>The metabolic and molecular basis of inherited disease. Vol III. McGraw-Hill
          <year>2001</year>
<fpage>3421</fpage>
<lpage>3452</lpage>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cross</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Hare</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders</article-title>
<source/>J Inherit Metab Dis
          <year>2013</year>
<volume>36</volume>
<issue>2</issue>
<fpage>189</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="doi">10.1007/s10545-012-9572-0</pub-id>
<pub-id pub-id-type="pmid">23385295</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zafeiriou</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Batzios</surname>
<given-names>SP</given-names>
</name>
</person-group>
<article-title>Brain and spinal MR imaging findings in mucopolysaccharidoses: a review</article-title>
<source/>Am J Neuroradiol
          <year>2013</year>
<volume>34</volume>
<issue>1</issue>
<fpage>5</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.3174/ajnr.A2832</pub-id>
<pub-id pub-id-type="pmid">22790241</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Villani</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Gargiulo</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Faraonio</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Castaldo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gonzalez y Reyero</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Di Natale</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Cytokines, neurotrophins, and oxidative stress in brain disease from mucopolysaccharidosis IIIB</article-title>
<source/>J Neurosci Res
          <year>2007</year>
<volume>85</volume>
<issue>3</issue>
<fpage>612</fpage>
<lpage>622</lpage>
<pub-id pub-id-type="doi">10.1002/jnr.21134</pub-id>
<pub-id pub-id-type="pmid">17139681</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shapiro</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Escolar</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations—neurological signs and symptoms</article-title>
<source/>Mol Genet Metab
          <year>2017</year>
<volume>122S</volume>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2017.08.009</pub-id>
<pub-id pub-id-type="pmid">29074036</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holt</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Poe</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Escolar</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>Natural progression of neurological disease in mucopolysaccharidosis type II</article-title>
<source/>Pediatrics
          <year>2011</year>
<volume>127</volume>
<issue>5</issue>
<fpage>1258</fpage>
<lpage>1265</lpage>
<pub-id pub-id-type="doi">10.1542/peds.2010-1274</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Poe</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Escolar</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>Early clinical markers of central nervous system involvement in mucopolysaccharidosis type II</article-title>
<source/>J Pediatr
          <year>2011</year>
<volume>159</volume>
<issue>2</issue>
<fpage>320</fpage>
<lpage>326</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpeds.2011.03.019</pub-id>
<pub-id pub-id-type="pmid">21530981</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cleary</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Wraith</surname>
<given-names>JE</given-names>
</name>
</person-group>
<article-title>Management of mucopolysaccharidosis type III</article-title>
<source/>Arch Dis Child
          <year>1993</year>
<volume>69</volume>
<issue>3</issue>
<fpage>403</fpage>
<lpage>406</lpage>
<pub-id pub-id-type="doi">10.1136/adc.69.3.403</pub-id>
<pub-id pub-id-type="pmid">8215557</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Węgrzyn</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Jakóbkiewicz-Banecka</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Narajczyk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wiśniewski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Piotrowska</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gabig-Cimińska</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different?</article-title>
<source/>Med Hypotheses
          <year>2010</year>
<volume>75</volume>
<issue>6</issue>
<fpage>605</fpage>
<lpage>609</lpage>
<pub-id pub-id-type="doi">10.1016/j.mehy.2010.07.044</pub-id>
<pub-id pub-id-type="pmid">20732748</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Potegal</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yund</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Rudser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Delaney</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nestrasil</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mucopolysaccharidosis type IIIA presents as a variant of Klüver-Bucy syndrome</article-title>
<source/>J Clin Exp Neuropsychol
          <year>2013</year>
<volume>35</volume>
<issue>6</issue>
<fpage>608</fpage>
<lpage>616</lpage>
<pub-id pub-id-type="doi">10.1080/13803395.2013.804035</pub-id>
<pub-id pub-id-type="pmid">23745734</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shapiro</surname>
<given-names>E</given-names>
</name>
<name>
<surname>King</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rudser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rumsey</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yund</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The neurobehavioral phenotype in mucopolysaccharidosis type IIIB: an exploratory study</article-title>
<source/>Mol Genet Metab Rep
          <year>2016</year>
<volume>6</volume>
<fpage>41</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgmr.2016.01.003</pub-id>
<pub-id pub-id-type="pmid">26918231</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Escolar</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Horovitz</surname>
<given-names>DDG</given-names>
</name>
<name>
<surname>Lampe</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Amartino</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Practical management of behavioral problems in mucopolysaccharidoses disorders</article-title>
<source/>Mol Genet Metab
          <year>2017</year>
<volume>122S</volume>
<fpage>35</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2017.09.010</pub-id>
<pub-id pub-id-type="pmid">29170079</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Grioni</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Contri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Furlan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Rigoldi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rovelli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Parini</surname>
<given-names>R</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Parini</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Andria</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Epilepsy in mucopolysaccharidosis: clinical features and outcome</article-title>
<source/>Lysosomal storage diseases: early diagnosis and new treatments
          <year>2010</year>
<publisher-loc>Montrouge</publisher-loc>
<publisher-name>John Libbey Eurotext</publisher-name>
<fpage>73</fpage>
<lpage>80</lpage>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scarpa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lourenço</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Amartino</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>Epilepsy in mucopolysaccharidosis disorders</article-title>
<source/>Mol Genet Metab
          <year>2017</year>
<volume>122S</volume>
<fpage>55</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2017.10.006</pub-id>
<pub-id pub-id-type="pmid">29170080</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haskins</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Animal models for mucopolysaccharidosis disorders and their clinical relevance</article-title>
<source/>Acta Paediatr
          <year>2007</year>
<volume>96</volume>
<issue>455</issue>
<fpage>56</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="doi">10.1111/j.1651-2227.2007.00211.x</pub-id>
<pub-id pub-id-type="pmid">17391445</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scarpa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Orchard</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>PI</given-names>
</name>
<name>
<surname>Haskins</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Escolar</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Giugliani</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Treatment of brain disease in the mucopolysaccharidoses</article-title>
<source/>Mol Genet Metab
          <year>2017</year>
<volume>122S</volume>
<fpage>25</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2017.10.007</pub-id>
<pub-id pub-id-type="pmid">29153844</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muenzer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wraith</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>LA</given-names>
</name>
</person-group>
<article-title>International consensus panel on management and treatment of mucopolysaccharidosis I</article-title>
<source/>Pediatrics
          <year>2009</year>
<volume>123</volume>
<issue>1</issue>
<fpage>19</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1542/peds.2008-0416</pub-id>
<pub-id pub-id-type="pmid">19117856</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shapiro</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Nestrasil</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Rudser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Delaney</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kovac</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurocognition across the spectrum of mucopolysaccharidosis type I: age, severity, and treatment</article-title>
<source/>Mol Genet Metab
          <year>2015</year>
<volume>116</volume>
<issue>1–2</issue>
<fpage>61</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2015.06.002</pub-id>
<pub-id pub-id-type="pmid">26095521</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krivit</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>EG</given-names>
</name>
</person-group>
<article-title>Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III</article-title>
<source/>Curr Opin Neurol
          <year>1999</year>
<volume>12</volume>
<issue>2</issue>
<fpage>167</fpage>
<lpage>176</lpage>
<pub-id pub-id-type="doi">10.1097/00019052-199904000-00007</pub-id>
<pub-id pub-id-type="pmid">10226749</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Ru</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Boelens</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>van der Lee</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Mahlaoui</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure</article-title>
<source/>Orphanet J Rare Dis
          <year>2011</year>
<volume>6</volume>
<fpage>55</fpage>
<pub-id pub-id-type="doi">10.1186/1750-1172-6-55</pub-id>
<pub-id pub-id-type="pmid">21831279</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poe</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Chagnon</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Escolar</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Early treatment is associated with improved cognition in Hurler syndrome</article-title>
<source/>Ann Neurol
          <year>2014</year>
<volume>76</volume>
<issue>5</issue>
<fpage>747</fpage>
<lpage>753</lpage>
<pub-id pub-id-type="doi">10.1002/ana.24246</pub-id>
<pub-id pub-id-type="pmid">25103575</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aldenhoven</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wynn</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Orchard</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>O'Meara</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Veys</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study</article-title>
<source/>Blood
          <year>2015</year>
<volume>125</volume>
<issue>13</issue>
<fpage>2164</fpage>
<lpage>2172</lpage>
<pub-id pub-id-type="doi">10.1182/blood-2014-11-608075</pub-id>
<pub-id pub-id-type="pmid">25624320</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shapiro</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Guler</surname>
<given-names>OE</given-names>
</name>
<name>
<surname>Rudser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Delaney</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bjoraker</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Whitley</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An exploratory study of brain function and structure in mucopolysaccharidosis type I: long term observations following hematopoietic cell transplantation (HCT)</article-title>
<source/>Mol Genet Metab
          <year>2012</year>
<volume>107</volume>
<issue>1–2</issue>
<fpage>116</fpage>
<lpage>121</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2012.07.016</pub-id>
<pub-id pub-id-type="pmid">22867884</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Whitley</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Cooksley</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rudser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cagle</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurocognitive and neuropsychiatric phenotypes associated with the mutation L238Q of the α-L-iduronidase gene in Hurler–Scheie syndrome</article-title>
<source/>Mol Genet Metab
          <year>2014</year>
<volume>111</volume>
<issue>2</issue>
<fpage>123</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2013.11.014</pub-id>
<pub-id pub-id-type="pmid">24368159</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rudser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kunin-Batson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>King</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Whitley</surname>
<given-names>CB</given-names>
</name>
</person-group>
<article-title>Association of somatic burden of disease with age and neuropsychological measures in attenuated mucopolysaccharidosis types I, II and VI</article-title>
<source/>Mol Genet Metab Rep
          <year>2016</year>
<volume>7</volume>
<fpage>27</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgmr.2016.03.006</pub-id>
<pub-id pub-id-type="pmid">27114913</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Sannaa</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Bay</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Barbouth</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Benhayoun</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Goizet</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Guelbert</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships</article-title>
<source/>Orphanet J Rare Dis
          <year>2015</year>
<volume>10</volume>
<fpage>131</fpage>
<pub-id pub-id-type="doi">10.1186/s13023-015-0344-4</pub-id>
<pub-id pub-id-type="pmid">26446585</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grosse</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Lam</surname>
<given-names>WKK</given-names>
</name>
<name>
<surname>Wiggins</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Kemper</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>Cognitive outcomes and age of detection of severe mucopolysaccharidosis type 1</article-title>
<source/>Genet Med
          <year>2017</year>
<volume>19</volume>
<issue>9</issue>
<fpage>975</fpage>
<lpage>982</lpage>
<pub-id pub-id-type="doi">10.1038/gim.2016.223</pub-id>
<pub-id pub-id-type="pmid">28125077</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<mixed-citation publication-type="other">Donati M, Pasquini E, Spada M, Polo G, Burlina A. Newborn screening in mucopolysaccharidoses. Ital J Pediatr. 2018. 10.1186/s13052-018-0551-4.</mixed-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ribeiro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mota</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Toralles</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Correia</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Horovitz</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>A clinical study of 77 patients with mucopolysaccharidosis type II</article-title>
<source/>Acta Paediatr Suppl
          <year>2007</year>
<volume>96</volume>
<issue>455</issue>
<fpage>63</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1111/j.1651-2227.2007.00212.x</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parini</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rigoldi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tedesco</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Boffi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Brambilla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bertoletti</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Enzymatic replacement therapy for Hunter disease: up to 9 years experience with 17 patients</article-title>
<source/>Mol Genet Metab Rep
          <year>2015</year>
<volume>3</volume>
<fpage>65</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgmr.2015.03.011</pub-id>
<pub-id pub-id-type="pmid">26937399</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manara</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Priante</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Grimaldi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Santoro</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Astarita</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Barone</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain and spine MRI features of Hunter disease: frequency, natural evolution and response to therapy</article-title>
<source/>J Inherit Metab Dis
          <year>2011</year>
<volume>34</volume>
<issue>3</issue>
<fpage>763</fpage>
<lpage>780</lpage>
<pub-id pub-id-type="doi">10.1007/s10545-011-9317-5</pub-id>
<pub-id pub-id-type="pmid">21465231</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vedolin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>IV</given-names>
</name>
<name>
<surname>Komlos</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schuch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Puga</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>LL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Correlation of MR imaging and MR spectroscopy findings with cognitive impairment in mucopolysaccharidosis II</article-title>
<source/>AJNR Am J Neuroradiol
          <year>2007</year>
<volume>28</volume>
<issue>6</issue>
<fpage>1029</fpage>
<lpage>1033</lpage>
<pub-id pub-id-type="doi">10.3174/ajnr.A0510</pub-id>
<pub-id pub-id-type="pmid">17569950</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Styner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Muenzer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Poe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Escolar</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Correlation of automated volumetric analysis of brain MR imaging with cognitive impairment in a natural history study of mucopolysaccharidosis II</article-title>
<source/>AJNR Am J Neuroradiol
          <year>2010</year>
<volume>31</volume>
<issue>7</issue>
<fpage>1319</fpage>
<lpage>1323</lpage>
<pub-id pub-id-type="doi">10.3174/ajnr.A2032</pub-id>
<pub-id pub-id-type="pmid">20203116</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yund</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Rudser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kovac</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Nestrasil</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Raiman</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cognitive, medical, and neuroimaging characteristics of attenuated mucopolysaccharidosis type II</article-title>
<source/>Mol Genet Metab
          <year>2015</year>
<volume>114</volume>
<issue>2</issue>
<fpage>170</fpage>
<lpage>177</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2014.12.299</pub-id>
<pub-id pub-id-type="pmid">25541100</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barone</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nigro</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Triulzi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Musumeci</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fiumara</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pavone</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Clinical and neuroradiological follow-up in mucopolysaccharidosis type III (Sanfilippo syndrome)</article-title>
<source/>Neuropediatrics
          <year>1999</year>
<volume>30</volume>
<issue>5</issue>
<fpage>270</fpage>
<lpage>274</lpage>
<pub-id pub-id-type="doi">10.1055/s-2007-973503</pub-id>
<pub-id pub-id-type="pmid">10598840</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meyer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kossow</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mühlhausen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ullrich</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Braulke</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A)</article-title>
<source/>Pediatrics
          <year>2007</year>
<volume>120</volume>
<issue>5</issue>
<fpage>1255</fpage>
<lpage>1261</lpage>
<pub-id pub-id-type="doi">10.1542/peds.2007-0282</pub-id>
<pub-id pub-id-type="pmid">18055674</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valstar</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Marchal</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Grootenhuis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Colland</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Wijburg</surname>
<given-names>FA</given-names>
</name>
</person-group>
<article-title>Cognitive development in patients with mucopolysaccharidosis type III (Sanfilippo syndrome)</article-title>
<source/>Orphanet J Rare Dis
          <year>2011</year>
<volume>6</volume>
<fpage>43</fpage>
<pub-id pub-id-type="doi">10.1186/1750-1172-6-43</pub-id>
<pub-id pub-id-type="pmid">21689409</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buhrman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Thakkar</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Poe</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Escolar</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>Natural history of Sanfilippo syndrome type A</article-title>
<source/>J Inherit Metab Dis
          <year>2014</year>
<volume>37</volume>
<issue>3</issue>
<fpage>431</fpage>
<lpage>437</lpage>
<pub-id pub-id-type="doi">10.1007/s10545-013-9661-8</pub-id>
<pub-id pub-id-type="pmid">24271936</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shapiro</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Nestrasil</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Delaney</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Rudser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kovac</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A prospective natural history study of mucopolysaccharidosis type IIIA</article-title>
<source/>J Pediatr
          <year>2016</year>
<volume>170</volume>
<fpage>278</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpeds.2015.11.079</pub-id>
<pub-id pub-id-type="pmid">26787381</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berger-Plantinga</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Vanneste</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Groener</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>van Schooneveld</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>Adult-onset dementia and retinitis pigmentosa due to mucopolysaccharidosis III-C in two sisters</article-title>
<source/>J Neurol
          <year>2004</year>
<volume>251</volume>
<issue>4</issue>
<fpage>479</fpage>
<lpage>481</lpage>
<pub-id pub-id-type="doi">10.1007/s00415-004-0368-5</pub-id>
<pub-id pub-id-type="pmid">15083297</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Valstar</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Bruggenwirth</surname>
<given-names>HT</given-names>
</name>
<name>
<surname>Olmer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wevers</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Verheijen</surname>
<given-names>FW</given-names>
</name>
<name>
<surname>Poorthuis</surname>
<given-names>BJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mucopolysaccharidosis type IIIB may predominantly present with an attenuated clinical phenotype</article-title>
<source/>J Inherit Metab Dis
          <year>2010</year>
<volume>33</volume>
<issue>6</issue>
<fpage>759</fpage>
<lpage>767</lpage>
<pub-id pub-id-type="doi">10.1007/s10545-010-9199-y</pub-id>
<pub-id pub-id-type="pmid">20852935</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cross</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bigger</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Wraith</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Mahon</surname>
<given-names>LV</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An investigation of the middle and late behavioural phenotypes of mucopolysaccharidosis type-III</article-title>
<source/>J Neurodev Disord
          <year>2014</year>
<volume>6</volume>
<issue>1</issue>
<fpage>46</fpage>
<pub-id pub-id-type="doi">10.1186/1866-1955-6-46</pub-id>
<pub-id pub-id-type="pmid">25657821</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shapiro</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Nestrasil</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wey</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rudser</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Delaney</surname>
<given-names>KA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Quantifying behaviors of children with Sanfilippo syndrome: the Sanfilippo Behavior Rating Scale</article-title>
<source/>Mol Genet Metab.
          <year>2015</year>
<volume>114</volume>
<issue>4</issue>
<fpage>594</fpage>
<lpage>598</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2015.02.008</pub-id>
<pub-id pub-id-type="pmid">25770355</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fraser</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gason</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wraith</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Delatycki</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Sleep disturbances in Sanfilippo syndrome: a parental questionnaire</article-title>
<source/>Arch Dis Child
          <year>2005</year>
<volume>90</volume>
<issue>12</issue>
<fpage>1239</fpage>
<lpage>1242</lpage>
<pub-id pub-id-type="doi">10.1136/adc.2004.065482</pub-id>
<pub-id pub-id-type="pmid">16301549</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mariotti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Della Marca</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Iuvone</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vernacotola</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ricci</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Mennuni</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Mazza</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Sleep disorders in Sanfilippo syndrome: a polygraphic study</article-title>
<source/>Clin Electroencephalogr
          <year>2003</year>
<volume>34</volume>
<issue>1</issue>
<fpage>18</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1177/155005940303400108</pub-id>
<pub-id pub-id-type="pmid">12515448</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahon</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Lomax</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cross</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hare</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Wraith</surname>
<given-names>JE</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Assessment of sleep in children with mucopolysaccharidosis type III</article-title>
<source/>PLoS One
          <year>2014</year>
<volume>9</volume>
<issue>2</issue>
<fpage>e84128</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0084128</pub-id>
<pub-id pub-id-type="pmid">24504123</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mumford</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Mahon</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bigger</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Canal</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hare</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Actigraphic investigation of circadian rhythm functioning and activity levels in children with mucopolysaccharidosis type III (Sanfilippo syndrome)</article-title>
<source/>J Neurodev Disord
          <year>2015</year>
<volume>7</volume>
<issue>1</issue>
<fpage>31</fpage>
<pub-id pub-id-type="doi">10.1186/s11689-015-9126-5</pub-id>
<pub-id pub-id-type="pmid">26388955</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Canal</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>FL</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Wraith</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Wynn</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bigger</surname>
<given-names>BW</given-names>
</name>
</person-group>
<article-title>Circadian rhythm and suprachiasmatic nucleus alterations in the mouse model of mucopolysaccharidosis IIIB</article-title>
<source/>Behav Brain Res
          <year>2010</year>
<volume>209</volume>
<issue>2</issue>
<fpage>212</fpage>
<lpage>220</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2010.01.045</pub-id>
<pub-id pub-id-type="pmid">20138090</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rumsey</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Rudser</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Delaney</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Potegal</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Whitley</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Acquired autistic behaviors in children with mucopolysaccharidosis type IIIA</article-title>
<source/>J Pediatr
          <year>2014</year>
<volume>164</volume>
<issue>5</issue>
<fpage>1147</fpage>
<lpage>1151</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpeds.2014.01.007</pub-id>
<pub-id pub-id-type="pmid">24582005</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolfenden</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wittkowski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hare</surname>
<given-names>DJ</given-names>
</name>
</person-group>
<article-title>Symptoms of autism spectrum disorder (ASD) in individuals with mucopolysaccharide disease type III (Sanfilippo Syndrome): a systematic review</article-title>
<source/>J Autism Dev Disord
          <year>2017</year>
<volume>47</volume>
<issue>11</issue>
<fpage>3620</fpage>
<lpage>3633</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-017-3262-6</pub-id>
<pub-id pub-id-type="pmid">28856504</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wijburg</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Węgrzyn</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Burton</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Tylki-Szymańska</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder</article-title>
<source/>Acta Paediatr
          <year>2013</year>
<volume>102</volume>
<issue>5</issue>
<fpage>462</fpage>
<lpage>470</lpage>
<pub-id pub-id-type="doi">10.1111/apa.12169</pub-id>
<pub-id pub-id-type="pmid">23336697</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muenzer</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations</article-title>
<source/>J Pediatr
          <year>2004</year>
<volume>144</volume>
<issue>5 Suppl</issue>
<fpage>S27</fpage>
<lpage>S34</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpeds.2004.01.052</pub-id>
<pub-id pub-id-type="pmid">15126981</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montaño</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Lock-Hock</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Szlago</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Greenstein</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical course of sly syndrome (mucopolysaccharidosis type VII)</article-title>
<source/>J Med Genet
          <year>2016</year>
<volume>53</volume>
<issue>6</issue>
<fpage>403</fpage>
<lpage>418</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2015-103322</pub-id>
<pub-id pub-id-type="pmid">26908836</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venkat-Raman</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sebire</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>KW</given-names>
</name>
</person-group>
<article-title>Recurrent fetal hydrops due to mucopolysaccharidoses type VII</article-title>
<source/>Fetal Diagn Ther
          <year>2006</year>
<volume>21</volume>
<issue>3</issue>
<fpage>250</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.1159/000091350</pub-id>
<pub-id pub-id-type="pmid">16601332</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wallace</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Prutting</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Gerber</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>Degeneration of speech, language, and hearing in a patient with mucopolysaccharidosis VII</article-title>
<source/>Int J Pediatr Otorhinolaryngol
          <year>1990</year>
<volume>19</volume>
<issue>2</issue>
<fpage>97</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="doi">10.1016/0165-5876(90)90215-D</pub-id>
<pub-id pub-id-type="pmid">2115509</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Islam</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Vervoort</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lissens</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hoo</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Valentino</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Sly</surname>
<given-names>WS</given-names>
</name>
</person-group>
<article-title>Beta-Glucuronidase P408S, P415L mutations: evidence that both mutations combine to produce an MPS VII allele in certain Mexican patients</article-title>
<source/>Hum Genet
          <year>1996</year>
<volume>98</volume>
<issue>3</issue>
<fpage>281</fpage>
<lpage>284</lpage>
<pub-id pub-id-type="doi">10.1007/s004390050207</pub-id>
<pub-id pub-id-type="pmid">8707294</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fox</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Volpe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bullaro</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kakkis</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Sly</surname>
<given-names>WS</given-names>
</name>
</person-group>
<article-title>First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient</article-title>
<source/>Mol Genet Metab
          <year>2015</year>
<volume>114</volume>
<issue>2</issue>
<fpage>203</fpage>
<lpage>208</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2014.10.017</pub-id>
<pub-id pub-id-type="pmid">25468648</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delaney</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Rudser</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Yund</surname>
<given-names>BD</given-names>
</name>
<name>
<surname>Whitley</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>Haslett</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>EG</given-names>
</name>
</person-group>
<article-title>Methods of neurodevelopmental assessment in children with neurodegenerative disease: Sanfilippo syndrome</article-title>
<source/>JIMD Rep
          <year>2014</year>
<volume>13</volume>
<fpage>129</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1007/8904_2013_269</pub-id>
<pub-id pub-id-type="pmid">24190801</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<mixed-citation publication-type="other">Barone R, Parini R. Lysosomal storage disorders. In: Riva D, Bulgheroni S, editors. Cognitive and behavioural neurology in developmental age: Mariani Foundation Paediatric Neurology Series: 28. 2015. London-Paris: John Libbey Eurotext Ltd; 2015. p. 147–66.</mixed-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shapiro</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bernstein</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Barbier</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Buracchio</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Como</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions</article-title>
<source/>Mol Genet Metab
          <year>2016</year>
<volume>118</volume>
<issue>2</issue>
<fpage>65</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2016.04.006</pub-id>
<pub-id pub-id-type="pmid">27132782</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janzen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Delaney</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>EG</given-names>
</name>
</person-group>
<article-title>Cognitive and adaptive measurement endpoints for clinical trials in mucopolysaccharidoses types I, II, and III: a review of the literature</article-title>
<source/>Mol Genet Metab
          <year>2017</year>
<volume>121</volume>
<issue>2</issue>
<fpage>57</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2017.05.005</pub-id>
<pub-id pub-id-type="pmid">28506702</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shapiro</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Escolar</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Delaney</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>JJ</given-names>
</name>
</person-group>
<article-title>Assessments of neurocognitive and behavioral function in the mucopolysaccharidoses</article-title>
<source/>Mol Genet Metab
          <year>2017</year>
<volume>122S</volume>
<fpage>8</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2017.09.007</pub-id>
<pub-id pub-id-type="pmid">29128371</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van der Lee</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Morton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ebbink</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Escolar</surname>
<given-names>ML</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cognitive endpoints for therapy development for neuronopathic mucopolysaccharidoses: results of a consensus procedure</article-title>
<source/>Mol Genet Metab
          <year>2017</year>
<volume>121</volume>
<issue>2</issue>
<fpage>70</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2017.05.004</pub-id>
<pub-id pub-id-type="pmid">28501294</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guffon</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Forest</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Fouilhoux</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Froissart</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years</article-title>
<source/>J Pediatr
          <year>2009</year>
<volume>154</volume>
<fpage>733</fpage>
<lpage>737</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpeds.2008.11.041</pub-id>
<pub-id pub-id-type="pmid">19167723</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vellodi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>E</given-names>
</name>
<name>
<surname>New</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pot-Mees</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hugh-Jones</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Bone marrow transplantation for Sanfilippo disease type B</article-title>
<source/>J Inherit Metab Dis
          <year>1992</year>
<volume>15</volume>
<fpage>911</fpage>
<lpage>918</lpage>
<pub-id pub-id-type="doi">10.1007/BF01800232</pub-id>
<pub-id pub-id-type="pmid">1293388</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<mixed-citation publication-type="other">Concolino D, Deodato F, Parini R. Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr. 2018. 10.1186/s13052-018-0558-x.</mixed-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calias</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Banks</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Begley</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Scarpa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dickson</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Intrathecal delivery of protein therapeutics to the brain: a critical reassessment</article-title>
<source/>Pharmacol Ther
          <year>2014</year>
<volume>144</volume>
<issue>2</issue>
<fpage>114</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2014.05.009</pub-id>
<pub-id pub-id-type="pmid">24854599</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dickson</surname>
<given-names>PI</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>AH</given-names>
</name>
</person-group>
<article-title>Intrathecal enzyme replacement therapy for mucopolysaccharidosis I: translating success in animal models to patients</article-title>
<source/>Curr Pharm Biotechnol
          <year>2011</year>
<volume>12</volume>
<issue>6</issue>
<fpage>946</fpage>
<lpage>955</lpage>
<pub-id pub-id-type="doi">10.2174/138920111795542642</pub-id>
<pub-id pub-id-type="pmid">21506913</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calias</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Papisov</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Savioli</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Belov</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<issue>1</issue>
<fpage>e30341</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0030341</pub-id>
<pub-id pub-id-type="pmid">22279584</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>King</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Beard</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hassiotis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Trim</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Snel</surname>
<given-names>MF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain</article-title>
<source/>J Inherit Metab Dis
          <year>2015</year>
<volume>38</volume>
<issue>2</issue>
<fpage>341</fpage>
<lpage>350</lpage>
<pub-id pub-id-type="doi">10.1007/s10545-014-9790-8</pub-id>
<pub-id pub-id-type="pmid">25421091</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dickson</surname>
<given-names>PI</given-names>
</name>
<name>
<surname>Kaitila</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Harmatz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mlikotic</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Victoroff</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I</article-title>
<source/>Mol Genet Metab
          <year>2015</year>
<volume>116</volume>
<issue>1–2</issue>
<fpage>69</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2015.07.005</pub-id>
<pub-id pub-id-type="pmid">26260077</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muenzer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hendriksz</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Vijayaraghavan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Santra</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II</article-title>
<source/>Genet Med
          <year>2016</year>
<volume>18</volume>
<issue>1</issue>
<fpage>73</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1038/gim.2015.36</pub-id>
<pub-id pub-id-type="pmid">25834948</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Breen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Heap</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Rust</surname>
<given-names>S</given-names>
</name>
<name>
<surname>de Ruijter</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tump</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A phase 1/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA</article-title>
<source/>Mol Genet Metab
          <year>2016</year>
<volume>118</volume>
<issue>3</issue>
<fpage>198</fpage>
<lpage>205</lpage>
<pub-id pub-id-type="doi">10.1016/j.ymgme.2016.05.006</pub-id>
<pub-id pub-id-type="pmid">27211612</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>De Castro Lopez</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Muschol</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Cleary</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shaywitz</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Cahan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Grover</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<source/>Preliminary safety and pharmacodynamic response data from a phase 1/2 study of ICV BMN 250, a novel enzyme replacement therapy for the treatment of Sanfilippo B syndrome (MPS IIIB)
          <year>2017</year>
<publisher-loc>San Diego</publisher-loc>
<publisher-name>Presentation (LB-12) at 13th Annual World Symposium</publisher-name>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolf</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Banerjee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hackett</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Whitley</surname>
<given-names>CB</given-names>
</name>
<name>
<surname>McIvor</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>WC</given-names>
</name>
</person-group>
<article-title>Gene therapy for neurologic manifestations of mucopolysaccharidoses</article-title>
<source/>Expert Opin Drug Deliv
          <year>2015</year>
<volume>12</volume>
<issue>2</issue>
<fpage>283</fpage>
<lpage>296</lpage>
<pub-id pub-id-type="doi">10.1517/17425247.2015.966682</pub-id>
<pub-id pub-id-type="pmid">25510418</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tardieu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zérah</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Husson</surname>
<given-names>B</given-names>
</name>
<name>
<surname>de Bournonville</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Deiva</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Adamsbaum</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial</article-title>
<source/>Hum Gene Ther
          <year>2014</year>
<volume>25</volume>
<issue>6</issue>
<fpage>506</fpage>
<lpage>516</lpage>
<pub-id pub-id-type="doi">10.1089/hum.2013.238</pub-id>
<pub-id pub-id-type="pmid">24524415</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tardieu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zérah</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gougeon</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Ausseil</surname>
<given-names>J</given-names>
</name>
<name>
<surname>de Bournonville</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Husson</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial</article-title>
<source/>Lancet Neurol
          <year>2017</year>
<volume>16</volume>
<issue>9</issue>
<fpage>712</fpage>
<lpage>720</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(17)30169-2</pub-id>
<pub-id pub-id-type="pmid">28713035</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giugliani</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Federhen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vairo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Vanzella</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pasqualim</surname>
<given-names>G</given-names>
</name>
<name>
<surname>da Silva</surname>
<given-names>LM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Emerging drugs for the treatment of mucopolysaccharidoses</article-title>
<source/>Expert Opin Emerg Drugs
          <year>2016</year>
<volume>21</volume>
<issue>1</issue>
<fpage>9</fpage>
<lpage>26</lpage>
<pub-id pub-id-type="doi">10.1517/14728214.2016.1123690</pub-id>
<pub-id pub-id-type="pmid">26751109</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schuh</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Baldo</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Teixeira</surname>
<given-names>HF</given-names>
</name>
</person-group>
<article-title>Nanotechnology applied to treatment of mucopolysaccharidoses</article-title>
<source/>Expert Opin Drug Deliv
          <year>2016</year>
<volume>13</volume>
<issue>12</issue>
<fpage>1709</fpage>
<lpage>1718</lpage>
<pub-id pub-id-type="doi">10.1080/17425247.2016.1202235</pub-id>
<pub-id pub-id-type="pmid">27322551</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<mixed-citation publication-type="other">Fecarotta S, Gasperini S, Parenti G. New treatments for the Mucopolysaccharidoses: from pathophysiology to therapy. Ital J Pediatr. 2018. 10.1186/s13052-018-0560-3.</mixed-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<mixed-citation publication-type="other">Fraldi A, Serafini M, Sorrentino NC, Gentner B, Aiuti A, Bernardo ME. Gene therapy for mucopolysaccharidoses: in vivo and ex vivo approaches. Ital J Pediatr. 2018. 10.1186/s13052-018-0556-z.</mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>